Compile Data Set for Download or QSAR

Found 2516 hits Enz. Inhib. hit(s) with Target = 'Kallikrein-1'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Kallikrein-1 (Homo sapiens (Human))	BDBM50034582 (CHEMBL2448441 | Peptide boronate) Show SMILES Br.[H][C@@]12CC3CC(C3(C)C)[C@]1(C)OB(O2)C(CCC\C(S)=N\N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1 |TLB:11:10:7:5,THB:12:10:7:5,14:2:7:5| Show InChI InChI=1S/C37H50BN5O6S.BrH/c1-36(2)26-21-29(36)37(3)30(22-26)48-38(49-37)31(17-10-18-32(50)42-39)41-33(44)28-16-11-19-43(28)34(45)27(20-24-12-6-4-7-13-24)40-35(46)47-23-25-14-8-5-9-15-25;/h4-9,12-15,26-31H,10-11,16-23,39H2,1-3H3,(H,40,46)(H,41,44)(H,42,50);1H/t26?,27-,28-,29?,30+,31?,37-;/m0./s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.00490	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Thrombosis Research Institute Curated by ChEMBL					Assay Description Binding affinity against kallikrein				J Med Chem 38: 1511-22 (1995) BindingDB Entry DOI: 10.7270/Q2QR4W57
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357210 (US10214512, Example 151-a) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](C[C@H](C)CCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.160	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357151 ((Z)-5-(3-Chloro-2,6-difluorophenyl)-2-(15-chloro-2...) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3Cl)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.210	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357155 ((Z)-5-(3-chloro-2,6-difluorophenyl)-2-(24-((methox...) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)[C@H](CCC[C@@H](C)C(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.240	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357153 ((Z)-5-(3-Chloro-2,6-difluorophenyl)-2-(15-ethyl-24...) Show SMILES CCc1[nH]c2nc1-c1ccc(NC(=O)OC)cc1NC(=O)CCCCC2c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.260	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357026 (5-(5-Chloro-2-(1H-tetrazol-1-yl)phenyl)-2-(24-((me...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCCC(c3cccc-2c3)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cnnn2)c1 Show InChI InChI=1S/C32H28ClN7O4/c1-44-32(42)35-24-11-12-25-20-5-4-6-21(15-20)26(7-2-3-8-31(41)36-28(25)17-24)30-13-9-22(18-40(30)43)27-16-23(33)10-14-29(27)39-19-34-37-38-39/h4-6,9-19,26H,2-3,7-8H2,1H3,(H,35,42)(H,36,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.290	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357192 (US10214512, Example 145-a) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C3CC3)[C@H](CCC[C@@H](C)C(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)cccc1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.300	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357094 (US10214512, Example 71) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cc-2ncc3F)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cnnn2)c1 |r| Show InChI InChI=1S/C31H26ClFN8O4/c1-45-31(43)36-20-8-9-22-26-14-24(25(33)15-34-26)21(4-2-3-5-30(42)37-27(22)13-20)29-10-6-18(16-41(29)44)23-12-19(32)7-11-28(23)40-17-35-38-39-40/h6-17,21H,2-5H2,1H3,(H,36,43)(H,37,42)/t21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.330	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357152 ((Z)-5-(3-chloro-2,6-difluorophenyl)-2-(24-((methox...) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.340	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357057 (US10214512, Example 37) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cccc-2c3)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cc(Cl)nn2)c1 |r| Show InChI InChI=1S/C33H28Cl2N6O4/c1-45-33(43)36-24-11-12-25-20-5-4-6-21(15-20)26(7-2-3-8-32(42)37-28(25)17-24)30-13-9-22(18-41(30)44)27-16-23(34)10-14-29(27)40-19-31(35)38-39-40/h4-6,9-19,26H,2-3,7-8H2,1H3,(H,36,43)(H,37,42)/t26-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.360	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357188 (US10214512, Example 143-b) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCC[C@@H](C)C(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)cccc1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.400	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-14 (Homo sapiens (Human))	BDBM50124906 (CHEMBL3623776) Show SMILES [H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@]([H])(NC(=O)[C@@]([H])(NC(=O)CNC(=O)[C@H](CC(N)=O)NC2=O)[C@@H](C)O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N2CCC[C@@]2([H])C(=O)N2CCC[C@@]2([H])C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N1 |r| Show InChI InChI=1S/C60H97N19O19S2/c1-7-27(3)43-54(93)71-35-25-99-100-26-36(72-55(94)45(29(5)81)73-42(85)23-66-47(86)32(21-40(61)83)68-52(91)37-14-10-18-77(37)57(96)33(22-41(62)84)69-50(35)89)51(90)76-46(30(6)82)56(95)67-31(13-9-17-65-60(63)64)48(87)70-34(24-80)49(88)75-44(28(4)8-2)59(98)79-20-12-16-39(79)58(97)78-19-11-15-38(78)53(92)74-43/h27-39,43-46,80-82H,7-26H2,1-6H3,(H2,61,83)(H2,62,84)(H,66,86)(H,67,95)(H,68,91)(H,69,89)(H,70,87)(H,71,93)(H,72,94)(H,73,85)(H,74,92)(H,75,88)(H,76,90)(H4,63,64,65)/t27-,28-,29+,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,43-,44-,45-,46-/m0/s1	KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	0.400	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Queensland University of Technology Curated by ChEMBL					Assay Description Inhibition of KLK14 (unknown origin) expressed in Sf9 cells using Ac-YANR-pNA substrate by spectrophotometry method				J Med Chem 58: 8257-68 (2015) Article DOI: 10.1021/acs.jmedchem.5b01148 BindingDB Entry DOI: 10.7270/Q2PR7XSJ
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357166 (US10214512, Example 122 | US10214512, Example 125) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)cccc1C(F)(F)F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.430	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357143 ((Z)-5-(5-Chloro-2-(difluoromethoxy)phenyl)-2-(24-(...) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1cc(Cl)ccc1OC(F)F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.430	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357065 ((S)-2-(24-(((2-(tert-butoxy)ethoxy)carbonyl)amino)...) Show SMILES CC(C)(C)OCCOC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cccc-2c3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r| Show InChI InChI=1S/C36H36ClF2N3O5/c1-36(2,3)47-18-17-46-35(44)40-25-12-13-26-22-7-6-8-23(19-22)27(9-4-5-10-32(43)41-30(26)20-25)31-16-11-24(21-42(31)45)33-29(38)15-14-28(37)34(33)39/h6-8,11-16,19-21,27H,4-5,9-10,17-18H2,1-3H3,(H,40,44)(H,41,43)/t27-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.440	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357110 (9-(5-(5-chloro-2-(1h-tetrazol-1-yl)phenyl)-1-oxido...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCCC(c3cc-2[n+]([O-])cc3F)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cnnn2)c1 Show InChI InChI=1S/C31H26ClFN8O5/c1-46-31(43)35-20-8-9-22-26(13-20)36-30(42)5-3-2-4-21(24-14-29(22)41(45)16-25(24)33)28-10-6-18(15-40(28)44)23-12-19(32)7-11-27(23)39-17-34-37-38-39/h6-17,21H,2-5H2,1H3,(H,35,43)(H,36,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.460	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357139 ((Z)-5-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)-2-(24-...) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1cc(Cl)ccc1-n1cnnn1 Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.490	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357206 (US10214512, Example 150-a) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCC[C@@H](C)C(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(OC(F)F)ccc(F)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.510	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357099 (5-(3-chloro-2,6-difluorophenyl)-2-((5R,9S)-15-fluo...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)[C@H](C)CCC[C@@H](c3cc-2ncc3F)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r| Show InChI InChI=1S/C31H26ClF3N4O4/c1-16-4-3-5-19(27-11-6-17(15-39(27)42)28-23(33)10-9-22(32)29(28)35)21-13-25(36-14-24(21)34)20-8-7-18(37-31(41)43-2)12-26(20)38-30(16)40/h6-16,19H,3-5H2,1-2H3,(H,37,41)(H,38,40)/t16-,19+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.530	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357022 (5-(5-Chloro-2-(1H-tetrazol-1-yl)phenyl)-2-((5R,9S)...) Show SMILES C[C@@H]1CCC[C@@H](c2cccc(c2)-c2cc(F)ccc2NC1=O)c1ccc(c[n+]1[O-])-c1cc(Cl)ccc1-n1cnnn1 |r| Show InChI InChI=1S/C31H26ClFN6O2/c1-19-4-2-7-25(20-5-3-6-21(14-20)26-16-24(33)10-11-28(26)35-31(19)40)30-12-8-22(17-39(30)41)27-15-23(32)9-13-29(27)38-18-34-36-37-38/h3,5-6,8-19,25H,2,4,7H2,1H3,(H,35,40)/t19-,25+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.590	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357137 ((Z)-5-(3-chloro-2,6-difluorophenyl)-2-(24-((methox...) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.600	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357161 (US10214512, Example 117) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)[C@H](CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1cc(F)ccc1-n1cnnn1 |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.650	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357174 (US10214512, Example 130) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(OC(F)F)ccc(F)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.660	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357055 (US10214512, Example 35) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cccc-2c3)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-c2cnco2)c1 |r| Show InChI InChI=1S/C34H29ClN4O5/c1-43-34(41)37-25-11-13-26-21-5-4-6-22(15-21)27(7-2-3-8-33(40)38-30(26)17-25)31-14-9-23(19-39(31)42)29-16-24(35)10-12-28(29)32-18-36-20-44-32/h4-6,9-20,27H,2-3,7-8H2,1H3,(H,37,41)(H,38,40)/t27-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357196 (US10214512, Example 146-a) Show SMILES CCc1[nH]c2nc1-c1ccc(NC(=O)OC)cc1NC(=O)[C@H](C)CCC[C@@H]2c1ccc(c[n+]1[O-])-c1c(F)cccc1OC(F)F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.710	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357168 (US10214512, Example 124) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)c(Cl)ccc1C(F)F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.730	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357172 (US10214512, Example 128) Show SMILES Cc1[nH]c2nc1-c1ccc(N)cc1NC(=O)CCCC[C@@H]2c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.740	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357150 ((Z)-5-(3-chloro-2,6-difluorophenyl)-2-(24-((ethoxy...) Show SMILES CCOC(=O)Nc1ccc2-c3c[nH]c(n3)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.770	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357157 (US10214512, Example 114-c) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)[C@@H](CCC[C@@H](C)C(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.780	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357164 (US10214512, Example 120) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCCCC(=O)Cc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(F)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.780	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357056 (5-(5-chloro-2-(4-(difluoromethyl)-1H-1,2,3-triazol...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCCC(c3cccc-2c3)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cc(nn2)C(F)F)c1 Show InChI InChI=1S/C34H29ClF2N6O4/c1-47-34(45)38-24-11-12-25-20-5-4-6-21(15-20)26(7-2-3-8-32(44)39-28(25)17-24)31-13-9-22(18-43(31)46)27-16-23(35)10-14-30(27)42-19-29(33(36)37)40-41-42/h4-6,9-19,26,33H,2-3,7-8H2,1H3,(H,38,45)(H,39,44)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.810	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357059 (US10214512, Example 39) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cccc-2c3)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cc(nn2)C(F)(F)F)c1 |r| Show InChI InChI=1S/C34H28ClF3N6O4/c1-48-33(46)39-24-11-12-25-20-5-4-6-21(15-20)26(7-2-3-8-32(45)40-28(25)17-24)30-13-9-22(18-44(30)47)27-16-23(35)10-14-29(27)43-19-31(41-42-43)34(36,37)38/h4-6,9-19,26H,2-3,7-8H2,1H3,(H,39,46)(H,40,45)/t26-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.810	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357058 (US10214512, Example 38) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cccc-2c3)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cc(nn2)C2CC2)c1 |r| Show InChI InChI=1S/C36H33ClN6O4/c1-47-36(45)38-27-13-14-28-23-5-4-6-24(17-23)29(7-2-3-8-35(44)39-31(28)19-27)34-15-11-25(20-43(34)46)30-18-26(37)12-16-33(30)42-21-32(40-41-42)22-9-10-22/h4-6,11-22,29H,2-3,7-10H2,1H3,(H,38,45)(H,39,44)/t29-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.950	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357141 ((Z)-5-(3-Chloro-6-(difluoromethoxy)-2-fluorophenyl...) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)c(Cl)ccc1OC(F)F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.02	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357149 ((Z)-2-(24-Amino-4-OXO-11H-3-aza-1(4,2)-imidazola-2...) Show SMILES Nc1ccc2-c3c[nH]c(n3)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)ccc(Cl)c1F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.02	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357096 (US10214512, Example 73) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cc-2ccn3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r| Show InChI InChI=1S/C30H25ClF2N4O4/c1-41-30(39)35-19-7-8-20-17-12-13-34-24(14-17)21(4-2-3-5-27(38)36-25(20)15-19)26-11-6-18(16-37(26)40)28-23(32)10-9-22(31)29(28)33/h6-16,21H,2-5H2,1H3,(H,35,39)(H,36,38)/t21-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.08	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357194 (US10214512, Example 145-c) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C3CC3)[C@H](CCC[C@H](C)C(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)cccc1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-14 (Homo sapiens (Human))	BDBM50125021 (CHEMBL3623779) Show SMILES [H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@]([H])(NC(=O)[C@@]([H])(NC(=O)CNC(=O)[C@H](CC(N)=O)NC2=O)[C@@H](C)O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@@]2([H])C(=O)N2CCC[C@@]2([H])C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N1 |r| Show InChI InChI=1S/C58H92N20O20S2/c1-5-25(2)42-52(93)71-33-23-99-100-24-34(72-53(94)43(26(3)80)73-41(85)21-65-45(86)29(18-38(59)82)67-50(91)35-11-7-15-76(35)55(96)30(19-39(60)83)69-48(33)89)49(90)75-44(27(4)81)54(95)66-28(10-6-14-64-58(62)63)46(87)70-32(22-79)47(88)68-31(20-40(61)84)56(97)78-17-9-13-37(78)57(98)77-16-8-12-36(77)51(92)74-42/h25-37,42-44,79-81H,5-24H2,1-4H3,(H2,59,82)(H2,60,83)(H2,61,84)(H,65,86)(H,66,95)(H,67,91)(H,68,88)(H,69,89)(H,70,87)(H,71,93)(H,72,94)(H,73,85)(H,74,92)(H,75,90)(H4,62,63,64)/t25-,26+,27+,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,42-,43-,44-/m0/s1	KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem	Article PubMed	1.20	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Queensland University of Technology Curated by ChEMBL					Assay Description Inhibition of KLK14 (unknown origin) expressed in Sf9 cells using Ac-YANR-pNA substrate by spectrophotometry method				J Med Chem 58: 8257-68 (2015) Article DOI: 10.1021/acs.jmedchem.5b01148 BindingDB Entry DOI: 10.7270/Q2PR7XSJ
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357140 ((Z)-5-(5-chloro-2-(trifluoromethoxy)phenyl)-2-(24-...) Show SMILES COC(=O)Nc1ccc2-c3c[nH]c(n3)C(CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1cc(Cl)ccc1OC(F)(F)F Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.21	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357118 (5-(3-Chloro-2,6-difluorophenyl)-2-(16-fluoro-24-((...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)[C@H](C)CCC[C@@H](c3ccc(F)c-2c3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r| Show InChI InChI=1S/C32H27ClF3N3O4/c1-17-4-3-5-21(28-13-7-19(16-39(28)42)29-26(35)12-10-24(33)30(29)36)18-6-11-25(34)23(14-18)22-9-8-20(37-32(41)43-2)15-27(22)38-31(17)40/h6-17,21H,3-5H2,1-2H3,(H,37,41)(H,38,40)/t17-,21+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.29	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357226 ((Z)-5-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)pheny...) Show SMILES [O-][n+]1cc(ccc1C1CCCCC(=O)Nc2ccc(F)cc2-c2nc1c[nH]2)-c1c(F)c(Cl)ccc1-n1cnnn1 Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.35	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357191 (US10214512, Example 144) Show SMILES CCc1[nH]c2nc1-c1ccc(NC(=O)OC)cc1NC(=O)C(C)CCC[C@@H]2c1ccc(c[n+]1[O-])-c1c(F)cccc1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.35	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357231 (US10214512, Example 166-a) Show SMILES C[C@@H]1CCC[C@@H](c2cccc(c2)-c2c(NC1=O)cnn2C(F)F)c1ccc(c[n+]1[O-])-c1cc(Cl)ccc1-n1cc(Cl)nn1 |r| Show InChI InChI=1S/C30H25Cl2F2N7O2/c1-17-4-2-7-22(18-5-3-6-19(12-18)28-24(36-29(17)42)14-35-41(28)30(33)34)26-10-8-20(15-40(26)43)23-13-21(31)9-11-25(23)39-16-27(32)37-38-39/h3,5-6,8-17,22,30H,2,4,7H2,1H3,(H,36,42)/t17-,22+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.39	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357167 (US10214512, Example 123) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCCCC(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(F)c(Cl)ccc1C(F)(F)F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.41	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357075 (5-(5-chloro-2-(1h-tetrazol-1-yl)phenyl)-2-(15-fluo...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCCC(c3cc(F)cc-2c3)c2ccc(c[n+]2[O-])-c2cc(Cl)ccc2-n2cnnn2)c1 Show InChI InChI=1S/C32H27ClFN7O4/c1-45-32(43)36-24-8-9-25-20-12-21(14-23(34)13-20)26(4-2-3-5-31(42)37-28(25)16-24)30-10-6-19(17-41(30)44)27-15-22(33)7-11-29(27)40-18-35-38-39-40/h6-18,26H,2-5H2,1H3,(H,36,43)(H,37,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.43	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357100 (5-(3-chloro-2,6-difluorophenyl)-2-((5S,9S)-15-fluo...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)[C@@H](C)CCC[C@@H](c3cc-2ncc3F)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r| Show InChI InChI=1S/C31H26ClF3N4O4/c1-16-4-3-5-19(27-11-6-17(15-39(27)42)28-23(33)10-9-22(32)29(28)35)21-13-25(36-14-24(21)34)20-8-7-18(37-31(41)43-2)12-26(20)38-30(16)40/h6-16,19H,3-5H2,1-2H3,(H,37,41)(H,38,40)/t16-,19-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.5	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357208 (US10214512, Example 150-c) Show SMILES COC(=O)Nc1ccc2-c3nc([nH]c3C)[C@H](CCC[C@H](C)C(=O)Nc2c1)c1ccc(c[n+]1[O-])-c1c(OC(F)F)ccc(F)c1F |r| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.5	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357066 ((S)-5-(3-chloro-2,6-difluorophenyl)-2-(24-(((2-hyd...) Show SMILES OCCOC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cccc-2c3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r| Show InChI InChI=1S/C32H28ClF2N3O5/c33-25-11-12-26(34)30(31(25)35)21-8-13-28(38(42)18-21)24-6-1-2-7-29(40)37-27-17-22(36-32(41)43-15-14-39)9-10-23(27)19-4-3-5-20(24)16-19/h3-5,8-13,16-18,24,39H,1-2,6-7,14-15H2,(H,36,41)(H,37,40)/t24-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.53	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357033 (5-(3-Chloro-2,6-difluorophenyl)-2-(24-((methoxycar...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCCC(c3cccc-2c3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 Show InChI InChI=1S/C31H26ClF2N3O4/c1-41-31(39)35-21-10-11-22-18-5-4-6-19(15-18)23(7-2-3-8-28(38)36-26(22)16-21)27-14-9-20(17-37(27)40)29-25(33)13-12-24(32)30(29)34/h4-6,9-17,23H,2-3,7-8H2,1H3,(H,35,39)(H,36,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.55	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair
Kallikrein-1 (Homo sapiens (Human))	BDBM357048 (US10214512, Example 28 | methyl (9-(5-(3-chloro-2-...) Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCCC(c3cccc-2c3)c2ccc(cn2)-c2c(F)c(Cl)ccc2-n2cnnn2)c1 Show InChI InChI=1S/C32H27ClFN7O3/c1-44-32(43)37-22-10-11-24-20-6-4-5-19(15-20)23(7-2-3-8-29(42)38-27(24)16-22)26-13-9-21(17-35-26)30-28(41-18-36-39-40-41)14-12-25(33)31(30)34/h4-6,9-18,23H,2-3,7-8H2,1H3,(H,37,43)(H,38,42)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.57	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Merck Sharp & Dohme Corp. US Patent					Assay Description The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...				US Patent US10214512 (2019) BindingDB Entry DOI: 10.7270/Q2668GGN
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 2516 total )  |  Next  |  Last  >>

Jump to: